**Index**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC (antecedents/behaviour/consequences)</td>
<td>513–14</td>
</tr>
<tr>
<td>absence epilepsy/seizures</td>
<td></td>
</tr>
<tr>
<td>animal studies</td>
<td>51</td>
</tr>
<tr>
<td>atypical 153. See also Lennox-Gastaut syndrome</td>
<td></td>
</tr>
<tr>
<td>classification 112</td>
<td></td>
</tr>
<tr>
<td>epileptogenesis in vivo</td>
<td>61</td>
</tr>
<tr>
<td>hyperventilation</td>
<td>123</td>
</tr>
<tr>
<td>juvenile 131–2, 135–6 and learning disability/behaviour</td>
<td>489</td>
</tr>
<tr>
<td>management 406–7</td>
<td></td>
</tr>
<tr>
<td>psychiatric disorders 291, 522</td>
<td></td>
</tr>
<tr>
<td>typical 160, 164</td>
<td></td>
</tr>
<tr>
<td>video-EEG monitoring</td>
<td>284</td>
</tr>
<tr>
<td>See also childhood absence epilepsy</td>
<td></td>
</tr>
<tr>
<td>absolute refractory period</td>
<td>26</td>
</tr>
<tr>
<td>accidental deaths</td>
<td>341</td>
</tr>
<tr>
<td>acquired epileptic aphasia (Landau-Kleffner syndrome)</td>
<td>131–2, 140, 333–4, 339</td>
</tr>
<tr>
<td>acquired mechanisms of epileptogenesis 53</td>
<td></td>
</tr>
<tr>
<td>action potentials 25–6, 27, 96</td>
<td></td>
</tr>
<tr>
<td>activation clinic, King’s College Hospital, London 315–16</td>
<td></td>
</tr>
<tr>
<td>activation maps</td>
<td>266</td>
</tr>
<tr>
<td>active controls 372</td>
<td></td>
</tr>
<tr>
<td>active movement 24</td>
<td></td>
</tr>
<tr>
<td>acute electrocorticography</td>
<td>445, 447–50</td>
</tr>
<tr>
<td>acute experimental models</td>
<td>47–9</td>
</tr>
<tr>
<td>acute symptomatic seizures</td>
<td>53, 189, 190, 299</td>
</tr>
<tr>
<td>acute viral encephalitis, EEG application</td>
<td>213–16</td>
</tr>
<tr>
<td>acutely isolated neurons</td>
<td>31</td>
</tr>
<tr>
<td>adaptation action potentials</td>
<td>26</td>
</tr>
<tr>
<td>ADD (Antiepileptic Drug Development) program</td>
<td>367–8</td>
</tr>
<tr>
<td>adjustments, employment</td>
<td>550</td>
</tr>
<tr>
<td>adolescent syndromes. See childhood/adolescent epilepsy</td>
<td></td>
</tr>
<tr>
<td>AEDs (antiepileptic drugs)</td>
<td>46–7, 330–1, 403–4</td>
</tr>
<tr>
<td>behavioural/mental health effects</td>
<td>403–4, 413–14, 526</td>
</tr>
<tr>
<td>blood tests 300</td>
<td></td>
</tr>
<tr>
<td>BOLD effect 244</td>
<td></td>
</tr>
<tr>
<td>childhood epilepsy</td>
<td>135, 479–81</td>
</tr>
<tr>
<td>clinical neuropsychological evaluation</td>
<td>410</td>
</tr>
<tr>
<td>compliance 577</td>
<td></td>
</tr>
<tr>
<td>dose selection 369, 488</td>
<td></td>
</tr>
<tr>
<td>economics 581–2</td>
<td></td>
</tr>
<tr>
<td>elderly patients 487–8</td>
<td></td>
</tr>
<tr>
<td>GABA-mediated inhibitory transmission</td>
<td>354–6</td>
</tr>
<tr>
<td>glutamatergic neurotransmission</td>
<td>355</td>
</tr>
<tr>
<td>health-related quality of life</td>
<td>539</td>
</tr>
<tr>
<td>iatrogenic damage 66</td>
<td></td>
</tr>
<tr>
<td>idiopathic generalized epilepsies</td>
<td>166</td>
</tr>
<tr>
<td>interactions. See pharmacological interactions</td>
<td></td>
</tr>
<tr>
<td>interictal EEG</td>
<td>119</td>
</tr>
<tr>
<td>learning disability 484</td>
<td></td>
</tr>
<tr>
<td>mechanism of action</td>
<td>354, 357</td>
</tr>
<tr>
<td>migraine 293</td>
<td></td>
</tr>
<tr>
<td>monotherapy/polytherapy</td>
<td>372, 392, 393, 394–5</td>
</tr>
<tr>
<td>video-EEG monitoring</td>
<td>284</td>
</tr>
<tr>
<td>See also clinical trials; therapeutic drug monitoring; treatment gaps</td>
<td></td>
</tr>
<tr>
<td>AEDs, new 367, 380–2, 384</td>
<td></td>
</tr>
<tr>
<td>behavioural effects 404–5</td>
<td></td>
</tr>
<tr>
<td>neuropsychological effects</td>
<td>414</td>
</tr>
<tr>
<td>selected features of specific drugs 382–3, 396–400</td>
<td></td>
</tr>
<tr>
<td>under development 396–400</td>
<td></td>
</tr>
<tr>
<td>AEEDs, traditional 374–8, 379</td>
<td></td>
</tr>
<tr>
<td>behavioural/mental health effects</td>
<td>403–4, 413–14</td>
</tr>
<tr>
<td>neuropsychological effects</td>
<td>413–14</td>
</tr>
<tr>
<td>principles of drug treatment</td>
<td>374–5</td>
</tr>
<tr>
<td>toxicity 375, 376</td>
<td></td>
</tr>
<tr>
<td>aetiology of epilepsy. See causes</td>
<td></td>
</tr>
<tr>
<td>affective disorders 515–17</td>
<td></td>
</tr>
<tr>
<td>See also anxiety, depression</td>
<td></td>
</tr>
<tr>
<td>after-hyperpolarization</td>
<td>26</td>
</tr>
<tr>
<td>age-effects 329, 414. See also elderly patients</td>
<td></td>
</tr>
<tr>
<td>aggression, and epilepsy</td>
<td>524–5</td>
</tr>
<tr>
<td>agonist/antagonist pharmacology</td>
<td>19</td>
</tr>
<tr>
<td>alcohol use 330–1, 339, 590</td>
<td></td>
</tr>
<tr>
<td>algorithms, tractography</td>
<td>261</td>
</tr>
<tr>
<td>allosteric modulation, GABA system</td>
<td>355</td>
</tr>
<tr>
<td>Alpers disease (progressive neuronal degeneration of childhood with liver disease) 187</td>
<td></td>
</tr>
<tr>
<td>alpha brain waves 81</td>
<td></td>
</tr>
<tr>
<td>alternating psychoses</td>
<td>522</td>
</tr>
<tr>
<td>Alzheimer’s disease 183, 213, 330–1</td>
<td></td>
</tr>
<tr>
<td>ambulatory EEG 281</td>
<td></td>
</tr>
<tr>
<td>amobarbital procedure</td>
<td>61</td>
</tr>
<tr>
<td>AMPA receptors 40–1, 53–4, 356</td>
<td></td>
</tr>
<tr>
<td>amygdalo-hippocampectomy</td>
<td>431–2</td>
</tr>
<tr>
<td>anytal test (Wada test)</td>
<td>61, 415–16, 423</td>
</tr>
<tr>
<td>anatomy</td>
<td></td>
</tr>
<tr>
<td>CNS 8–15, 16</td>
<td></td>
</tr>
<tr>
<td>hippocampus 10, 37–9</td>
<td></td>
</tr>
<tr>
<td>Angelman syndrome 44, 181, 492–3</td>
<td></td>
</tr>
<tr>
<td>animal models 58, 464–5, 513</td>
<td></td>
</tr>
<tr>
<td>See also experimental models; laboratory studies</td>
<td></td>
</tr>
<tr>
<td>anoxia 97, 98, 213–14, 283</td>
<td></td>
</tr>
<tr>
<td>anterior temporal lobectomy</td>
<td>431, 432</td>
</tr>
<tr>
<td>antidepressant medication</td>
<td>516, 533, 534</td>
</tr>
<tr>
<td>antidiromic stimulation</td>
<td>33</td>
</tr>
<tr>
<td>antipsychotic medication</td>
<td>533, 534</td>
</tr>
<tr>
<td>anxiety 513, 518–19</td>
<td></td>
</tr>
<tr>
<td>clinical evaluation 411</td>
<td></td>
</tr>
<tr>
<td>families of epilepsy sufferers 546</td>
<td></td>
</tr>
<tr>
<td>marriage 545–6</td>
<td></td>
</tr>
<tr>
<td>and surgery 532</td>
<td></td>
</tr>
<tr>
<td>treatment 536–7</td>
<td></td>
</tr>
<tr>
<td>See also behavioural treatment</td>
<td></td>
</tr>
<tr>
<td>apnoea 289</td>
<td></td>
</tr>
<tr>
<td>artefacts, EEG 82–4</td>
<td></td>
</tr>
<tr>
<td>artificial membrane-channel preparations 31</td>
<td></td>
</tr>
<tr>
<td>aspiration 341</td>
<td></td>
</tr>
</tbody>
</table>
assessment. See investigations
association analysis 348–9
association areas, lesion studies 11–12
asterixis 181
atonic seizures 111
attention, neuropsychological evaluation 411
attention deficit hyperactivity disorder 291
A-type potassium channels 28–9
atypical absence seizures 153.
See also Lennox-Gastaut syndrome
atypical benign partial epilepsy 154–5
audiogenic epilepsy 464–5
auditory evoked potentials 220, 459
auditory stimuli, reflex epilepsy 459
auras 110, 277, 290–1, 293, 421
autoimmune disease 302–3
autism 110, 112, 282–3, 524–5,
585–6
autonomic failure 286
autonomic symptoms 109
autoregulatory systems 285
autosomal dominant cortical reflex myoclonus 176, 181
axons 17
bacterial meningitis 330–1
Baltic myoclonus epilepsy 74
band heterotopia 504
barbiturates 376
Batten disease 220, 221
beam former algorithms 270, 274
behavioural disorders, childhood epilepsy 526–8
differential diagnosis 297
and learning disability 484
behavioural effects of AEDs 403–5
new AEDs 404–5
older/established drugs 403–4,
413–14
behavioural treatment 513–14
benign childhood epilepsy with centrotemporal spikes (BECTS) 131–3, 134
EEG 200, 208–10
benign childhood epilepsy with occipital spasms. See Panayiotopoulos syndrome
benign epilepsy 158, 164.
See also idiopathic focal epilepsies
benign familial (idiopathic) neonatal convulsions 333–4
benign myoclonic epilepsy of infancy 161, 200, 204–7
benign paroxysmal vertigo 298
benzodiazepines 378, 408–9
bereavement. See Epilepsy Bereaved
beta brain waves 81
bilateral independent temporal interictal discharges 428
biochemical abnormalities 283, 300,
306–7, 337
biochemistry of neurotransmission 40–5
biofeedback 514. See also behavioural treatment
biological matrices, therapeutic drug monitoring 361
bio-psycho-social approaches 574
bipolar mood disorder 515–16
birth hazards 337
bizarre behaviours 288–9, 534
blinding, clinical trials 369
blood tests 300
BOLD (blood oxygenation-level dependent effect) 244, 266
brain activity, fMRI 245
brain damage
childhood epilepsy 527
EEG phenomenology 97, 98
perinatal 70
prevention 407–8, 409
secondary changes 64–6
brain diseases, EEG applications 213–16
brain slices 31, 47, 50, 55–7, 52
brain stem death 214–16
brain stimulation 436, 439, 442, 443.
See also single pulse electrical stimulation; vagus nerve stimulation
brain tumours. See tumours
breath-holding in children 297
brief seizures, management 407
British Epilepsy Association 564
brivaracetam 396
buccal midazolam 378, 409
budget impact studies 583
calcium ion channels 28, 48, 54, 353–4
calcium IT oscillating currents 50, 55
callosotomy, preoperative assessment 420
candidate genes 348
carbamazepine 135, 375, 377
benign epilepsy of childhood with centrotemporal spikes 132
everly patients 487
late-onset occipital epilepsy 134
pharmacological interactions 386–7, 388
therapeutic drug monitoring 362, 363
treatment gaps 556
cardiac arrhythmia 103–5
cardiology assessment 299
cardiovascular syndromes simulating epilepsy 285–6
care approaches. See joined-up primary-secondary care approach; primary care; specialist centres
carers, community support groups 576–7
carotid amobarbital test (Wada test) 61, 415–16, 423
case scenarios, paediatric epilepsy 307, 308, 312
case-control studies 330
catamenial seizures 476–7
caudate stimulation 442
causes
of death in epilepsy 341–2
of epilepsy 330
cell electrophysiology 22–9, 30
cell membranes. See membranes
cellular level epileptogenesis in vitro 54–5, 62
central nervous system (CNS), functional anatomy 8–15, 16
centrecephalic hypothesis 60–1
cerebellar atrophy 66
cerebral cortex 8–12
cerebral hemispheres 8–10, 13.
See also lateralization
cerebral malformations, 67–70
cerebral perfusion 285
cerebral trauma. See head injury
cerebral tumours. See tumours
cerebrovascular disease 330–1, 501–3
EEG 97–8, 502–3
chain reactions, excitatory neurotransmission 48
charities supporting epilepsy 564–5.
See also organizations/support services
cardiovascular syndromes simulating epilepsy (CAE) 131–2 135, 136, 161, 165
case scenarios
EEG 200, 204–7
case scenarios, paediatric epilepsy 131–2, 304, 307, 482, 540, 141
AEDs 479–81
behavioural/mental health effects 527
case scenarios 307, 308, 312
classification 131
cognitive decline 306–7
differential diagnosis 296–8, 339
EEG reporting sessions 318–19, 326, 327
epidemiology 337–9
health-related quality of life 540
management 478–82
Index

childhood/adolescent epilepsy (cont.)
neuroimaging 305–6
neurophysiology/EEG 304–5
non-genetic risk factors 331
other investigations 306–7
surgery 438–9, 440
syndromes 131–2
See also learning disability
chromosomal epilepsies 351, 492–3.
See also genetics; lissencephaly; ring chromosome
chronic encephalitis. See Rasmussen’s encephalitis
chronic epilepsy 6, 49–50
experimental models 49–51
neuroimaging indications 238
secondary changes 64–6
chronic interictal psychoses 522–3
chronic progressive epilepsy partialis continua of childhood (Kojewnikow syndrome) 131, 134–5, 333–4
chronically cultured neurons 31
classical conditioning
classification 107, 115–16, 117–18, 300–1
childhood/adolescent epilepsy 131, 338
EEG manifestations 113
evolution of 113–14
focal seizures 107–11
generalized seizures 107, 111–13
international classifications 107
multi-axial 307–8,
myoclonus, epileptic 183
neonatal seizures 142–3, 145
neuroimaging guidelines 237
newly diagnosed/chronic epilepsy, 300–1
other classifications 118
practical examples 116
psychogenic non-epileptic seizures 313
relevance 117
status epilepticus 468–9
terminology 107–8
video-EEG monitoring 283
See also diagnosis
clinical trials, AEDs 292, 369–73
health-related quality of life
measures 540
status epilepticus 472
clonic convulsions/seizures 111, 282–3
CLV (continuous low-voltage inactive EEG) 195–6
cobblestone complex 504
Cochrane reviews, new AEDs 381
Coffin Lowry syndrome 465
cognitive behavioural therapy
See also behavioural treatment
cognitive decline, investigations
302–3, 306–7
cognitive impairment, effects of AEDs 403
cohort studies 330
commissures, posterior/anterior 8
community support groups 576–7, 593
co-morbidity 530, 562
comparative genomic hybridization (CGH) 306
complex partial seizures 110, 406–7
compliance, medication 577
conditioning, classical/operant
confidentiality, patient 551, 554
continuous low-voltage inactive EEG (CLV) 195–6
continuous spike-wave during slow-wave sleep (CSWS) 131, 140–1, 490
contraception 474, 590
controls, clinical trials 369, 372
convulsions, clonic 282–3
convulsive movements 108
convulsive seizures, management 406
cornu ammonis 38
corpus callosum 8, 12, 67–8, 74, 418
cortical action-reflex myoclonus 183
cortical dysplasia 67–8, 506–8
cortical resection 75
cortical stimulation 442
corticobasal degeneration 183
corticoreticular epilepsies model 61
cost of illness studies 583
cost-effectiveness studies 583

counselling, psychodynamic 536–7
Creutzfeldt–Jakob disease (CJD) 101, 213, 214
criminal responsibility 585–6.
See also Disability Discrimination Act; Health and Safety at Work Act
cross-over studies, clinical trials 370
CT (computerized tomography) 224, 226–36. See also neuroimaging
cumulative incidence of epilepsy 330
current clamp recordings 33
cyanosis 282–3
cyclotymia 515
Davy, Sir Humphrey 3
dearth. See mortality; sudden unexpected death
declarative memory 262–3
definitions of epilepsy 6–7, 114, 329, 332
delayed rectifier potassium channels 28–9
delta brain waves 82
dementia 213, 214
dendrites 17
dentato-rubo-pallido-luysian atrophy (DRPLA) 186
depersonalization 292
depression 330–1, 513, 515–16, 545–6
definition 515
joined-up care approach 573–4
neuropsychological evaluation 411
risk factors 516
surgery effects 434, 532
treatment 515, 516.
See also behavioural treatment
dept electrodes 424
developing world, treatment gap 555–6,
developmental regression 310
diagnosis 6–7
elderly patients 486
electro-clinical 6–7
ictal EEG 128
molecular/genetic techniques 36
neonatal seizures 143–7
residential care/specialist centres 562
video-EEG monitoring 281–2, 282–3
See also classification; differential diagnosis; investigations
dialectic seizures 108
diazepam 378, 408
dietary measures 138, 154, 456–7
differential diagnosis 298
daudiogenic epilepsy 465
behavioural/psychiatric disorders 297
childhood epilepsy 296–8, 339
ictal EEG 128
movement disorders 294–5
neurological disorders 297–8
other possible conditions 296
psychiatric disorders simulating epilepsy 290
syncope 296
West syndrome/infantile spasms 151
See also specific conditions
diffuse neocortical atrophy 66
diffusion tensor imaging (DTI) 259–65
dipolar source localization 269–70
dipole electroencephalography 79
direct costs 581
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>disabling aspects of epilepsy, organizations/support services 570</td>
</tr>
<tr>
<td>dissociative seizures 313, 317, 529–31</td>
</tr>
<tr>
<td>clinical semiology 529, 530</td>
</tr>
<tr>
<td>definitions/terminology/classification 313, 529</td>
</tr>
<tr>
<td>diagnosis 297, 313, 315–16, 531</td>
</tr>
<tr>
<td>investigations 313–16</td>
</tr>
<tr>
<td>psychiatric co-morbidity 530</td>
</tr>
<tr>
<td>video-EEG monitoring 282–3</td>
</tr>
<tr>
<td>distributed source localization 270–1</td>
</tr>
<tr>
<td>DNA diagnosis 36. See also genetics</td>
</tr>
<tr>
<td>Doose syndrome (myoclonic-astatic epilepsy) 131, 138, 154, 200</td>
</tr>
<tr>
<td>EEG 208–9</td>
</tr>
<tr>
<td>dormant cell hypothesis 58</td>
</tr>
<tr>
<td>double cortex 505</td>
</tr>
<tr>
<td>Down syndrome 181, 493</td>
</tr>
<tr>
<td>Dravet syndrome. See severe myoclonic epilepsy of infancy</td>
</tr>
<tr>
<td>driving 335–6, 341, 540, 553–4</td>
</tr>
<tr>
<td>AED withdrawal 401, 554</td>
</tr>
<tr>
<td>elderly patients 487</td>
</tr>
<tr>
<td>joined-up approach 572</td>
</tr>
<tr>
<td>parents with epilepsy 547</td>
</tr>
<tr>
<td>drop attacks 111</td>
</tr>
<tr>
<td>drowning 341</td>
</tr>
<tr>
<td>drug use 590. See also AEDs; antiepileptic medication; antipsychotic medication; mood stabilizers; psychotropic drugs</td>
</tr>
<tr>
<td>DTI (diffusion tensor imaging) 259–65</td>
</tr>
<tr>
<td>DWI (diffusion-weighted imaging) 286–7</td>
</tr>
<tr>
<td>dysembryoplastic neuroepithelial tumour (DNT) 73</td>
</tr>
<tr>
<td>dysthymia 515</td>
</tr>
<tr>
<td>early (neonatal) myoclonic encephalopathy 152, 197–8</td>
</tr>
<tr>
<td>early infantile epileptic encephalopathy (Ohtahara syndrome) 152, 197</td>
</tr>
<tr>
<td>early myoclonic encephalopathy 184</td>
</tr>
<tr>
<td>early-onset benign occipital epilepsy. See Panayiotopoulos syndrome</td>
</tr>
<tr>
<td>East Kent scheme, primary care 558–9</td>
</tr>
<tr>
<td>ECG (REVEAL) 286</td>
</tr>
<tr>
<td>economics, health 581–4</td>
</tr>
<tr>
<td>ECT (electro-convulsive therapy) 330–1</td>
</tr>
<tr>
<td>education. See learning disability; public education</td>
</tr>
<tr>
<td>EEG (electroencephalography) 76, 80 case reporting sessions 318–19, 326–7</td>
</tr>
<tr>
<td>continuous low-voltage inactive 195–6</td>
</tr>
<tr>
<td>definition 191</td>
</tr>
<tr>
<td>indications 301</td>
</tr>
<tr>
<td>interpretation 77–8</td>
</tr>
<tr>
<td>intracranial 34</td>
</tr>
<tr>
<td>montages 78</td>
</tr>
<tr>
<td>recording methodology 76–7</td>
</tr>
<tr>
<td>recording/reviewing principles 76, 77–8</td>
</tr>
<tr>
<td>source reconstruction 266</td>
</tr>
<tr>
<td>techniques 191</td>
</tr>
<tr>
<td>terminology 79 types 305</td>
</tr>
<tr>
<td>See also ictal EEG; interictal EEG</td>
</tr>
<tr>
<td>EEG - normal phenomenology 81, 95</td>
</tr>
<tr>
<td>artefacts 82–4</td>
</tr>
<tr>
<td>children/neonates 191–4, 198–200</td>
</tr>
<tr>
<td>normal background 81–3, 84</td>
</tr>
<tr>
<td>normal transients/benign variants 83–93</td>
</tr>
<tr>
<td>state/age effects 95–4</td>
</tr>
<tr>
<td>EEG - pathological phenomenology, 96–7, 106</td>
</tr>
<tr>
<td>atypical benign partial epilepsy 154–5</td>
</tr>
<tr>
<td>brain diseases 213–16</td>
</tr>
<tr>
<td>cardiac arrhythmia 103–5</td>
</tr>
<tr>
<td>cerebrovascular disorders 97–8, 502–3</td>
</tr>
<tr>
<td>childhood absence epilepsy 135–6</td>
</tr>
<tr>
<td>children/neonates 194–6, 200, 212</td>
</tr>
<tr>
<td>continuous spike-waves during slow-wave sleep 141</td>
</tr>
<tr>
<td>Creutzfeldt–Jakob disease 100, 101</td>
</tr>
<tr>
<td>Dravet syndrome 157</td>
</tr>
<tr>
<td>early epileptic encephalopathies with suppression-burst EEG 152</td>
</tr>
<tr>
<td>early (neonatal) myoclonic encephalopathy 197–8</td>
</tr>
<tr>
<td>early infantile epileptic encephalopathy 197</td>
</tr>
<tr>
<td>encephalitis 99–102</td>
</tr>
<tr>
<td>encephalopathies, infancy/early childhood 200–6</td>
</tr>
<tr>
<td>hepatic encephalopathy 101–2, 103</td>
</tr>
<tr>
<td>hypoxic brain damage 97, 98</td>
</tr>
<tr>
<td>idiopathic focal epilepsies 208–11</td>
</tr>
<tr>
<td>idiopathic generalized epilepsies 164, 166, 204–10</td>
</tr>
<tr>
<td>juvenile absence epilepsy 136</td>
</tr>
<tr>
<td>juvenile myoclonic epilepsy 137</td>
</tr>
<tr>
<td>Landau Kleffner syndrome 140</td>
</tr>
<tr>
<td>late-onset occipital epilepsy 134</td>
</tr>
<tr>
<td>Lennox-Gastaut syndrome 138, 154 management applications 304–5</td>
</tr>
<tr>
<td>myoclonic-astatic epilepsy 139, 154</td>
</tr>
<tr>
<td>neonatal seizures 197–9</td>
</tr>
<tr>
<td>newly diagnosed/chronic epilepsy 300–1</td>
</tr>
<tr>
<td>occipital lobe epilepsies 161, 177–9</td>
</tr>
<tr>
<td>Panayiotopoulos syndrome 133, 160</td>
</tr>
<tr>
<td>preoperative assessment 428</td>
</tr>
<tr>
<td>rolandic epilepsy 158–9, 160</td>
</tr>
<tr>
<td>status epilepticus 102–5</td>
</tr>
<tr>
<td>temporal lobe epilepsy 170–1</td>
</tr>
<tr>
<td>tumours 97</td>
</tr>
<tr>
<td>typical absence seizures 160, 164</td>
</tr>
<tr>
<td>West syndrome/infantile spasms 151, 338</td>
</tr>
<tr>
<td>EEG-correlated fMRI 266–8, 301–2</td>
</tr>
<tr>
<td>elastic Van Gieson 35</td>
</tr>
<tr>
<td>elderly patients 486–8</td>
</tr>
<tr>
<td>electrical extracellular stimulation 33</td>
</tr>
<tr>
<td>electrical source imaging 269, 271. See also source localization</td>
</tr>
<tr>
<td>electrical status epilepticus of slow-wave sleep 490</td>
</tr>
<tr>
<td>electrocorticography, acute 445, 447–50</td>
</tr>
<tr>
<td>electrodes, intracranial EEG 424–5</td>
</tr>
<tr>
<td>electrographic seizures 52</td>
</tr>
<tr>
<td>electromagnetic theories, history 2–3</td>
</tr>
<tr>
<td>electron microscopy 36</td>
</tr>
<tr>
<td>electrophysiology of cells 22–9, 30</td>
</tr>
<tr>
<td>electrotetinography 217–22</td>
</tr>
<tr>
<td>emergency treatment 339, 409, 559. See also management</td>
</tr>
<tr>
<td>emotions, physiology 13–14</td>
</tr>
<tr>
<td>employment 552</td>
</tr>
<tr>
<td>encephalitis 99–102, 330–1</td>
</tr>
<tr>
<td>encephalopathy 184, 212–14</td>
</tr>
<tr>
<td>early childhood 153–5</td>
</tr>
<tr>
<td>first year of life 150–2</td>
</tr>
<tr>
<td>infancy/early childhood 200–6</td>
</tr>
<tr>
<td>epidemiology of epilepsy 329–31</td>
</tr>
<tr>
<td>cerebrovascular disease 502</td>
</tr>
<tr>
<td>childhood epilepsy 337, 338, 339</td>
</tr>
<tr>
<td>learning disability 483</td>
</tr>
<tr>
<td>non-genetic risk factors 331</td>
</tr>
<tr>
<td>status epilepticus 468</td>
</tr>
<tr>
<td>epidural peg electrodes 424–5</td>
</tr>
<tr>
<td>epilepsy partialis continua 176, 181, 333–4. See also Rasmussen’s encephalitis</td>
</tr>
<tr>
<td>Epilepsy Action 564</td>
</tr>
<tr>
<td>Epilepsy Bereaved 564, 592–3. See also sudden unexpected death</td>
</tr>
<tr>
<td>Epilepsy Surgery Inventory 541</td>
</tr>
<tr>
<td>epilepsy with continuous spike and wave during slow-wave sleep 333–4</td>
</tr>
<tr>
<td>epilepsy with generalized tonic-clonic seizures 165, 333–4</td>
</tr>
</tbody>
</table>
Index

epilepsy with myoclonic absences 165–6, 184
epileptic seizures, definitions 6
epileptiform discharges 119–22
epileptogenesis in vitro 52, 57
cellular level 50, 54–5, 56, 62
mechanisms 53
molecular level 53–4
network level (brain slices) 55–7
reactive (induced) seizures 53
stages 53
epileptogenesis in vivo 58, 59, 60–2, 63, 60
epileptogenic lesions 67
equality/inequality 549, 574–5
Equality Act (2010) 570
equilibrium potentials 23–4
eslicarbazepine acetate 362, 387
ethnic considerations, health-related quality of life 540
evoked potentials 217–23
role in epilepsy 219–21
examination. See history-taking;
physical examination
excitability, cell 24–5
excitation (resonance) 240
excitatory neurotransmission, 40–2
chain reactions 48
epileptogenesis 53–4
experimental models 47
excitatory postsynaptic potentials 25
excitement 513
exclusion criteria, clinical trials 369
executive functioning,
neuropsychological evaluation
411
exercise 513. See also behavioural treatment
experimental models 32, 46–51.
See also epileptogenesis in vitro;
laboratory studies
eyelid myoclonia with absences (Jeavons’ syndrome) 112, 140, 165, 166
eyewitnesses 276, 290–1, 296–8
factitious disorder (Munchausen’s syndrome) 529
families of epilepsy sufferers 521, 546–7
community support groups 576–7
practical advice 547
FDG tracers 252–3, 301–2
febrile convulsions 156–7, 330–1
epidemiology 338
and febrile seizures 156
generalized epilepsy with febrile seizures plus 157
neuropathology 71–2
severe myoclonic epilepsy of infancy 157
felbamate 362, 382, 405
females with epilepsy 474–7, 493
fertility 546
fetal damage 70, 539
fimbria 8
fissures 8
fixation-off sensitive epilepsy
462–3
FLAIR (fluid-attenuated inversion-recovery) imaging 301
flumazenil tracers 252–3
fluoroelbamate 397
fMRI (functional MRI) 244–7, 301–2, 426
EEG-correlated 266–8, 301–2
focal cortical dysplasia 68–70
focal epilepsy
acute models 47–9
chronic models 49–50
ILAE classification 131
mechanisms 59, 60, 60
terminology 115, 132
Wylers’ hypothesis 58
See also frontal lobe epilepsy;
idioptic focal epilepsies
focal onset seizures, AEDs 480
focal seizures, electroclinical classification 107–8
autonomic symptoms 109
classification by site of origin 111
gelastic seizures 110
hemiconic seizures 111
with impaired consciousness 110
myoclonias 111
with preserved consciousness 109–10
psychic symptoms 109–10
sensory symptoms 109
terminology 108
focus localization 269–72, 283–4, 417–18, 421, 427
foramen ovale electrodes 424
forced normalization 522
forward problem 269
frontal association cortex, lesion studies 11–12
frontal lobe epilepsy 174–6
frontal lobe seizures, classification 111
frontal lobe surgery 450
fugue states 522
functional anatomy. See anatomy functional imaging 306. See also fMRI functional localization, history 2
functional neurosurgery 74, 418
functional surgery 436
fundraising, research 569
GABA (γ-aminobutyric acid) system 20, 42–5
AEDs, neurochemistry 354–6
B receptors 44
epileptogenesis at molecular level 54
epileptogenesis in vivo 62
GABA-transaminase 44
geneic defects 44
phasic/tonic inhibition 44
A receptors 42–4, 47
surround/recurrent inhibition 44–5
transporters 42
gabapentin 362, 382, 387, 404, 488
GABA-transaminase 44
gamma knife irradiation 436, 445
ganaxolone 397
ganglioglioma 73
Gastaut type late-onset occipital epilepsy 131–4
Gaucher disease 187
gelastic seizures 110, 444
gelegenheitsanfälle (acute symptomatic seizures) 189, 190, 299
gender and epilepsy 329, 521.
See also women with epilepsy
general anaesthesia 447–9
generalized epilepsies 183.
See also idiopathic generalized epilepsies
generalized epilepsy with febrile seizures plus (GEFS +) 44, 157
generalized seizures 60–2, 107, 111–13, 132, 480
generalized tonic-clonic seizures 163, 165
Genetically Epilepsy Prone Rat (GEPR) 50–1
genetics 330–1
basic principles 345–6
diagnosis 36
epilepsy classification 115
GABA receptors 44
investigations 306
mechanisms of epileptogenesis 53
methodology 347–9
neuropathology 75
progress 350–2
ring chromosome 20, 310–11, 492–3
Global Campaign against Epilepsy 579–80
glutamate 40–2
glutamate metabotropic receptors 42, 357
glutamatergic neurotransmission 255, 355
Goldman constant field flux 24
gradients, ion 23
grey matter 8, 20, 505
<table>
<thead>
<tr>
<th>Guidelines</th>
<th>305–6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Childhood epilepsy</td>
<td>480, 481</td>
</tr>
<tr>
<td>Management of epilepsy</td>
<td>478</td>
</tr>
<tr>
<td>New AEDs</td>
<td>381</td>
</tr>
<tr>
<td>Psychotropic drugs</td>
<td>535</td>
</tr>
<tr>
<td>Guilt</td>
<td>536</td>
</tr>
<tr>
<td>Gyri</td>
<td>8</td>
</tr>
<tr>
<td>Gyrus dentatus</td>
<td>38</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haemorrhage mechanisms</th>
<th>501–2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Half-life, AEDs</td>
<td>359</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hemispheres</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hemimegalencephaly</th>
<th>67</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemiclonic seizures</td>
<td>111</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health-related quality of life (HRQOL)</th>
<th>358–42, 570</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health economics</td>
<td>581–4</td>
</tr>
<tr>
<td>Health-related quality of life (HRQOL)</td>
<td>538–42, 570</td>
</tr>
<tr>
<td>Hemiconic seizures</td>
<td>111</td>
</tr>
<tr>
<td>Hemimegalencephaly</td>
<td>67–8</td>
</tr>
<tr>
<td>Hemispherectomy/hemispherotomy</td>
<td>75, 420, 432–3</td>
</tr>
<tr>
<td>Hemispheres, cerebral</td>
<td>8–10, 13</td>
</tr>
<tr>
<td>See also lateralization</td>
<td></td>
</tr>
<tr>
<td>Hepatic encephalography</td>
<td>101–2, 103, 213–14</td>
</tr>
<tr>
<td>Herpes simplex encephalitis</td>
<td>99, 100, 213–16</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>34, 42, 103, 213–14</td>
</tr>
<tr>
<td>Anatomy/connections</td>
<td>10, 37–9</td>
</tr>
<tr>
<td>Chronic epileptic brain damage</td>
<td>65–6</td>
</tr>
<tr>
<td>Epileptogenesis in vitro</td>
<td>56–7</td>
</tr>
<tr>
<td>Histochemistry</td>
<td>35, 65–7, 69, 74</td>
</tr>
<tr>
<td>Historical contexts</td>
<td>1–2, 5</td>
</tr>
<tr>
<td>Employment</td>
<td>548</td>
</tr>
<tr>
<td>ILAE</td>
<td>578–9</td>
</tr>
<tr>
<td>Personality</td>
<td>520</td>
</tr>
<tr>
<td>Psychiatry of epilepsy</td>
<td>3–4</td>
</tr>
<tr>
<td>Resident care/specialist centres</td>
<td>561</td>
</tr>
<tr>
<td>Social disorders</td>
<td>4</td>
</tr>
<tr>
<td>Temporal lobe epilepsy</td>
<td>168</td>
</tr>
<tr>
<td>Vascular/electromagnetic theories</td>
<td>2–3</td>
</tr>
</tbody>
</table>

| History-taking | 6, 276–8, 280 |
| Cardiovascular syndromes | 280 |
| Simulating epilepsy | 285 |
| Childhood epilepsy | 338 |
| Preoperative assessment | 421 |
| Hughlings Jackson, J. | 2–3, 168, 578 |

| Human Genome Project | 346 |
| Huntington’s disease | 183 |
| Hydantoin | 376 |
| Hydrogen nuclei | 240, 241 |
| Hyper-connection syndrome | 521 |
| Hyperekplexia | 294–5, 465 |
| Hyperkinetic seizures | 174 |
| Hypermotor seizures | 108, 174 |
| Hyperpolarization | 24, 25 |
| Hyperpolarizing inward rectification | 29 |
| Hypersynchrony, hippocampal | 56 |
| Hypocalcaemia | 283 |
| Hypoglycaemia | 283, 339 |
| Hypothalamic hamartomas | 67 |
| Hypoxic brain damage | 97, 98, 213–14, 283 |
| Hypsarrhythmia | 338, 150–1 |

| Iatrogenic damage, AEDs | 66 |
| Ictal EEG | 124–30, 134, 175 |
| Benign epilepsy of childhood with centrotemporal spikes | 132, 133–4 |
| Frontal lobe epilepsy | 175 |
| Infantile spasms/West syndrome | 200–3 |
| Preoperative assessment | 423 |
| Temporal lobe epilepsy | 170–1 |
| Idiopathic childhood occipital epilepsy of Gastaut | 200 |
| Idiopathic focal epilepsies | 116, 158–62 |
| EEG | 208–11 |
| Prognosis | 333–4 |
| Idiopathic generalized epilepsies | 116, 163–7 |
| EEG | 204–10 |
| Myoclonus | 183–4 |
| Prognosis | 333–4 |
| Idiopathic (primary) epilepsy | acute models | 48–9 |
| Chronic models | 50–1 |
| History | 2 |
| ILAE classification | 131 |
| Idiopathic photosensitive occipital epilepsy | 131, 134, 463 |
| ILAE (International League Against Epilepsy) | Global campaign against epilepsy | 579–80 |
| History | 578–9 |
| Neuroimaging guidelines | 237 |
| See also classification |
| Immunohistochemistry | 35–6 |

| In vitro experimental models | 31–3, 47 |
| See also epileptogenesis |
| In vivo experimental techniques/models | 34, 47 |
| Incidence of epilepsy | 329–30 |
| Inclusion criteria, clinical trials | 369 |
| Independence, lifestyle | 589 |
| Independent component analysis | 270 |
| Indirect brain stimulation | 436 |
| Indirect costs | 581 |
| Individualized therapeutic concentrations | 361–2 |
| Individual variations, reactions to AEDs | 358 |
| Inequality/equality | 549, 574–5 |
| Infantile spasms | 150–2 |
| Case scenarios | 309 |
| EEG | 200–3 |
| Epidemiology | 338 |
| Prognosis | 333–4 |
| Infants, epilepsy of epilepsy | 337 |
| Infection, CNS | 213–16 |
| Information sources, unit costs | 582–3 |
| Inhibitory neurons | 20 |
| Inhibitory neurotransmission | 42–5 |
| Epileptogenesis | 54 |
| Experimental models | 47 |
| Inhibitory postsynaptic potentials | 25 |
| Insula | 8, 111 |
| Intangible costs | 581 |
| Intelligence | 411, 521 |
| Intensive monitoring | 369 |
| See video-EEG monitoring |
| Intention-to-treat analyses | 369 |
| Interictal EEG | 52–124, 125, 130 |
| Frontal lobe epilepsy | 175 |
| Infantile spasms/West syndrome | 200–3 |
| Preoperative assessment | 422–3 |
| Temporal lobe epilepsy | 170–1 |
| International Bureau for Epilepsy | 579–80 |
| International classifications | 3, 107 |
| International League Against Epilepsy. See ILAE |
| Interneurons | 20 |
| Interventions. See management interventions |
| Intracellular electrodes | 32 |
| Intracranial EEG recordings | 34, 423–5 |
| Complications | 426 |
| Indications | 425–6 |
| Interpretation | 426–7 |
| Intractable epilepsy, new AEDs | 381 |
| Intraoperative (acute) electrocorticography | 445, 447–50 |
| Inverse problem | 269 |
Index

Landau-Kleffner syndrome (acquired epileptic aphasia) 131–2, 140, 333–4, 339
language disturbances
clinical neuropsychological evaluation 411
functional anatomy 12–13
lateralization 12–14, 246, 261–2
direction, fMRI 246
terminology 108
Wada test 415
late infantile neuronal ceroid lipofuscinosis 187
late-onset occipital epilepsy (Gastaut type) 131–4
lateral temporal lobe epilepsy 170
lateralization, cerebral hemispheres functional MRI 246
language function 12–14, 261–2, 415
memory function 415–16
preoperative assessment 421
laughing (gelastic) seizures 110, 444
law 585–6. See also Disability Discrimination Act; Health and Safety at Work Act
layers of cortex 20
lead toxicity 213–14
learning disability 483–5, 489–91
legal responsibility 585–6.
See also Disability Discrimination Act; Health and Safety at Work Act
legislation, UK 570
Lennox–Gastaut syndrome 131–2, 138, 139, 153–4, 493
EEG 200, 204–6
prognosis 333–4
lesemection 431–2
lesions
classification 114
epileptogenic 67
experimental studies 11–12, 34
stereotactic 74
See also neuraphology of epilepsy
Leskell Gamma Knife 436, 445
levetiracetam 364, 383, 389, 404, 487
lifestyle 589–90
AEDs withdrawal 401–2
avoiding accidental deaths 341
and prognosis 335–6
ligand-gated ion channels 353–7
limbic system 10, 13–14
linkage analysis 347–8
lissencephaly 67–8, 504
Liverpool Quality Battery 541
local drug application 34
localization, source 269–72, 283–4, 417–18, 421, 427
long-term epilepsy, joined-up primary–secondary care approach 573–4
long-term extension studies, AEDs 370
long-term placements, residential care/specialist centres 561–2
low-dose controls, AEDs 372
macrocephaly 67–8
magnetic resonance imaging. See MRI
magnetic source imaging 269.
See also source localization magnetoencephalography 273–5, 301–2
malformations of cortical development 506–9
PET 255
See also neurones migration abnormalities
malignant migrating partial seizures in infancy 200, 205, 518
malingering 529
management interventions 409
anxiety
behavioural 513–14, 527–8
catamelen seizures 477
cerebrovascular disease 503
childhood epilepsy 337, 478–82
depression 515–16
dissociative seizures 530–1
emergency treatment 409
hamartomas, hypothalamic 444
health-related quality of life measures 539–40
learning disability 484–5
photosensitivity 463
and prognosis 333
seizures 406–7
single seizures 336
status epilepticus 471–2
See also AEDs; emergency treatment; ketogenic diet; surgery; treatment gaps
manic episodes, definitions 515
marriage 545–6
maximal electroshock model 367
measures, health-related quality of life 540–1
medical history-taking. See history-taking; physical examination
diagnosis. See AEDs; antidepressant medication; antipsychotic medication; mood stabilizers; psychotropic drugs
MEG (magnetoencephalography) 273–5, 301–2

inversion recovery sequences 301
investigations, adult epilepsy 299, 300–1, 303
neuropsychological evaluation 410–12
psychogenic non-epileptic seizures 313–16
single seizures 336
inward-rectifying potassium channels 28–9
ion channels 22
ionic currents 273
irreversible side effects, AEDs 539
ischaemia mechanisms 501
isolated brain laboratory studies 31–2

Janz syndrome. See juvenile myoclonic epilepsy
Jeavons’ syndrome 112, 140, 165, 166
jerks (generalized myoclonic seizures) 112
joined-up primary-secondary care approach 572–3
Joint Epilepsy Council 564–5
juvenile absence epilepsy 131–2, 135–6, 164, 165, 200
juvenile Gaucher disease 187
juvenile myoclonic epilepsy (Janz syndrome) 131–2, 136–8, 161, 164–5
EEG 200, 208–10
genetic defects 44
lifestyle 590
JZP–4 397
kainate receptors 41, 356
ketogenic diet 138, 154, 456–7
kindling, experimental models 49, 50
King’s College Hospital, London 315–16, 452–4
knowledge/understanding of epilepsy 572–4, 577, 593. See also public education
Kojewnikow syndrome (chronic progressive epilepsy partialis continua of childhood) 131, 134–5, 333–4
L calcium channels 28
laboratory studies 31–6
photosensitivity 461–2
See also experimental models; neuropathology
lacrosamide 364, 382, 387
Lafora body disease 73, 185
laminar necrosis 64
laminogline 364, 377–8, 383, 389, 404, 488

more information
malignant hyperthermia 268
membranes, neuronal 17, 28
electrophysiology 22, 27–9
laboratory studies 31
potentials 22
receptors 19
resting behaviour 22–3
memory function
clinical evaluation 411
fMRI 246–7
parahippocampal gyrus 262–3
surgical outcomes 434
Wada test 415–16
Mendel, Gregor 345
Mendelian epilepsies 347–8
Mendel, Gregor 345
mendian epilepsy 434
mercury toxicity 213
meningitis, bacterial 330
mood state
montages, electroencephalography 78
motor cortex 9, 10–11, 246
motor skills, clinical
neuropsychological evaluation 411
mouth-to-mouth resuscitation 408
movement artefacts, fMRI 245
movement disorders 289, 294–5
MR-compatible EEG recording
systems 267
MRI (magnetic resonance imaging)
224, 225–6, 240
image formation 241–2
management of childhood epilepsy 305–6
negatives 256
newly diagnosed/chronic epilepsy 300–1
preoperative assessment 421–2
structural imaging 226–36, 227–36
temporal lobe epilepsy 170
volumetric 242
See also DTI; functional MRI; neuroimaging: NMR
MRS (magnetic resonance spectroscopy) 240, 242–3
multi-axial classification 308
multiple sclerosis 294, 330–1
multiple sleep latency test 288
multiple subpial transactions (MST) 418, 436
Munchausen’s syndrome 529
muscarinic-sensitive potassium currents 28–9
muscigenic epilepsy 464–5
myoclonic-astatic epilepsy. See Doose syndrome
myoclonus, epileptic 181–4
abnormalakes 112, 131, 140, 165–6
focal seizures 111
generalized myoclonic seizures 112
idiopathic generalized epilepsies 160, 183–4
management 407
negative 112, 181
neuropathology 73–4
progressive 183, 185–6, 188
variations 113, 116
N calcium channels 28
narcolepsy 283, 288–9, 465
nasal midazolam 378, 409
National Epilepsy Week 567
National Institute for Health and Clinical Excellence, neuroimaging guidelines 237
National Sentinel Clinical Audit of Epilepsy-related Death 567
National Society for Epilepsy (NSE) 564
natural history of epilepsy 333
negative myoclonus 112, 181
neonatal convulsions, prognosis 333–4
neonatal myoclonic encephalopathy 152, 197–8
neonatal seizures 142–6, 147–8, 149
EEG 197–9
Nernst equation 24
network level brain slices 55–7
neurocardiogenic syncope 286
neurochemistry, AEDs 353–7
neurochemistry/receptor pharmacology 17–21
neurodegenerative conditions
presenting with epilepsy 307
neuroimaging 224, 225–6
indications 237–9
management role 305–6
preoperative assessment 421–2
See also CT; DTI; MEG; MRI; MRS; PET; SPECT
neurological disease 297–9
neuromodulators 21
neuronal body 17
neuronal ceroid lipofuscinoses 220, 221
neurodes
anatomy, 17–20
inhibitory 20
laboratory studies 31
layers of cortex 20
migration abnormalities 504–5
neurochemistry/receptor pharmacology 19–20
thalamic 55
neuropathology of epilepsy 35, 64, 75
chronic epileptic brain damage 64–6
electron microscopy 36
febrile convulsions 71–2
genetics 75
histochemistry 35, 69, 74
immunohistochemistry 35–6
molecular/genetic techniques 36
myoclonic epilepsy 73–4
neurosurgery 58, 75
Rasmussen’s encephalitis 71–2
secondary neuropathological changes 64–7
status epilepticus 64
surgical specimens, handling 35
symptomatic epilepsy 67–71
trauma 66, 72
tumours 72–3

© in this web service Cambridge University Press

www.cambridge.org
<table>
<thead>
<tr>
<th>Index</th>
<th>603</th>
</tr>
</thead>
</table>

history-taking/physical examination 421
ictal EEG 423
indications for surgery/timing 419
interictal EEG 422–3
intracranial EEG 423–5
intracranial EEG complications 426
intracranial EEG indications 425–6
intracranial EEG interpretation 426–7
methods 420–1
 misconception 427–8
 neuroimaging 421–2
 neuropsychiatric assessment 421
 neuropsychology 422, 427
 phased evaluation 427–9
 residential care/specialist centres 562
 seizure semiology 298
 Wada test 423
 prevention
 epilepsy 330
 learning disability 489
 prevention, sudden unexpected death in epileptics 593
 primary care, role 557–60.
 See also joined-up primary–secondary care approach
 primary motor cortex 9, 10–11, 246
 primary parasomnias 298
 primidone 365, 389
 privacy, patient 536.
 See also confidentiality
 prodromal symptoms 110, 277, 515, 522
 prognosis, newly diagnosed/chronic epilepsy 332–4
 investigations/management 336
 after a single seizure 332, 335–6
 specific syndromes 333–4
 progressive myoclonus 183, 185–6, 188
 progressive neuronal degeneration of childhood with liver disease (Alpers disease) 187
 prolactin levels 282, 297–8
 proportionality mortality 340
 prospective cohort studies 330
 protein binding, AEDs 361, 385
 provoked (acute symptomatic) seizures 189, 190, 299
 pseudo-seizures 297
 psychiatric disorders associated with epilepsy 290, 292
 anxiety 518
 co-morbidity 530
 differential diagnosis 290, 297
 effects of surgery 434, 532
 history 3–4
 other disorders 291–2
 panic disorder 290–1
 See also psychoses
 psychic symptoms 109–10
 psychodynamic counselling 536–7
 psychogenic non-epileptic seizures.
 See dissociative seizures
 psychological impact of diagnosis/seizures, health-related quality of life 539
 psychomotor seizures 110
 psychoses of epilepsy 291, 522–3
 effects of AEDs 403, 407
 surgical outcomes 434, 532
 psycho-social history of patient 278
 psychotherapy, time-limited 536–7
 psychotropic drugs 533–5
 See also mood state
 puberty, precocious 444
 public education 566–7, 568.
 See also knowledge/understanding of epilepsy
 Purkinje cells 66
 pyramidal cells 20, 48
 Q calcium channels 28
 Quality and Outcomes Framework (QOF) 558, 574
 quality of life 538–42, 570
 Quality Of Life In Epilepsy Instruments (QOLIE) 541
 race, and epilepsy 329
 radon 222
 radial electrical currents 76
 radiosurgery, stereotactic 436
 Ramsay Hunt syndrome 74
 randomization, clinical trials,
 AEDs 369
 randomized clinical trials. See clinical trials
 Rasmussen’s encephalitis 134–5,
 510–12
 neuropathology of epilepsy 71–2
 prognosis 333–4
 reactive (induced) seizures 53, 189, 190, 299
 reading epilepsy 466, 467
 reasonable adjustments, employment 550
 receptor pharmacology 17–21
 rectal benzodiazepine administration 378, 408–9
 recurrent depressive disorder, definition 515.
 See also depression
 recurrent inhibition, GABA system 44–5
 reference ranges, AEDs 361–2, 366
 reflex epilepsy 6, 459–60.
 See also audiogenic epilepsy; photosensitivity
 reflex seizures 112–13
 rehabilitation 410.
 See also joined-up primary–secondary care approach
 relationships, and epilepsy 545.
 See also families of epilepsy
 sufferers; marriage
 relative refractory period 26
 relaxation, NMR 240–2
 relaxation techniques
 REM (rapid eye movement) sleep 287–8, 289
 remission, spontaneous 333
 renal excretion 386
 Repertory Grid Assessments 541
 research fundraising 569
 resective neurosurgery 74, 417–18,
 434–6, 444–5
 residential care/specialist centres 561–3
 resonance, NMR 240
 resource use economics 581–2
 respiratory syncope 297
 responsibility, legal 585–6.
 See also Disability Discrimination Act; Health and Safety at Work Act
 reticular reflex myoclonus 184
 retigabine 397–8
 retrospective cohort studies 330
 Rett syndrome 493
 rhythmic myoclonus 181
 right-hand grip rule 273
 ring chromosome 20, 310–11, 492–3
 risk factors
 cerebrovascular disease 502
 depression in epilepsy 516
 epidemiology 330–1
 learning disability 483–4
 surgery 418
 risk-taking lifestyles 589
 rodent models 465. See also animal models
 rolandic epilepsy 158–9, 160, 294
 rolandic fissure 8
 rotarod test 367
 rufinamide 383, 389–90
 safinamide 385
 sample size, clinical trials 369
 sampling time, therapeutic drug monitoring 360–1
 scales, health-related quality of life 540–1
 schizencephaly 67–8
schizophrenia-like psychoses of epilepsy 291, 522–3.
See also psychoses
school performance 547.
See also learning disability
sclerosis, tuberous 70
secondarily generalized seizures 50, 110
secondary parasomnias 298
seizure onset, terminology 108
seizure testing 398
self-image 543–6, 590
sensitivity analysis, health
economics 508
sensory evoked potentials 221–2
sensory symptoms, focal seizures 109
septum nuclei 8
septum pellucidum 8
sexual functioning 513, 521, 545–6, 590. See also behavioural
treatment
shame 536
sharp electrode technique 32
sharp waves, EEG 96
short-term assessment, residential
care/specialist centres 562
sialidosis 186
side effects, AEDs 354, 357, 401, 539. See also behavioural effects of AEDs
signal aperture magnetometry 274
simple partial seizures 109–10, 407
single-cell extracellular recordings 34
single-channel patch clamps 32
single-pulse electrical stimulation 450, 452–4, 455
situation related seizures 53, 189–90, 299
sleep deprivation 590
sleep disorders 283, 287–9
differential diagnosis 298
and learning disability 490
sleep physiology 15
slice cultures 31, 47, 50, 52, 55–7
social disorder, epilepsy as 4
sodium amytal test 61
sodium channels 27–8, 54, 157, 353–4
sodium valproate 137–8, 377
sodium–potassium currents 29
sodium–potassium pump 24
somatization 530
somatosensory cortex 9–11
somatosensory stimuli, reflex
epilepsy 459
source localization 269–72, 283–4, 417–18, 421, 427
South East Thames Paediatric Epilepsy
Interest Group 480
space-occupying lesions 214
spasms 111–12
specialist centres 561–3
SPECT (single positron emission
computed tomography) 248, 250–1
ictal 249
interictal 248
investigations, adult epilepsy 301–2
investigations, childhood
epilepsy 306
preoperative assessment 422
speech. See language
spikes. See action potentials
spike-related BOLD maps 267
spike-wave complexes 97
spontaneous remission 333
spontaneous seizures 53
SQUIDs (superconductive quantum
interference devices) 273
staining techniques, histochemistry
35, 65–7, 69, 74
standardized mortality ratio 340
staring symptoms 110, 112
startle epilepsy 464
state-dependent learning disability 489
statistical thresholds, fMRI 245
status epilepticus 468–70, 473
accidental deaths 341
convulsive 472–3
diagnosis/management 471–3
EEG 102–5
emergencies 339, 407–8
experimental models 49, 50
and learning disability 489
management 407
non-convulsive 473
randomized clinical trials 472
secondary neuropathological
changes 64
treatment principles 471–2
stereotactic
lesions 74
radiosurgery 436
thermocoagulation 445
stigma 526–7, 543–4. See also public
education
stimuli, epilepsy 284, 459–61
stiripentol 390
stress 513
stroke. See cerebrovascular disease
structural imaging 226–36, 227–36, 301, 305–6
study designs
clinical trials 370
epidemiological 330
functional MRI 245
health economics 583
sub-acute sclerosing panencephalitis 102, 213–16
subcortical structures 9, 15
subcutaneous pentylenetetrazol
model 367
subdural electrodes 424–5
subpial resection 74
substance misuse 330–1
subthalamic nucleus stimulation 442
subtle seizures 308–10
sudden unexpected death in epileptics
See also Epilepsy Bereaved;
mortality in epilepsy
suicides 341
sulci 8
superior longitudinal fasciculus 261–2
support groups 576–7, 593.
See also organizations/support
services
surgery 418, 434–7, 500, 417
case scenarios, paediatric epilepsy
308–9
and epilepsy 498–9
functional 418, 436
neuropathology 58, 75
neuropsychological evaluation 410
outcomes 434–6, 438–9
paediatric 438–40
psychiatric effects 532
resective 417–18, 434–6
specimen handling 35
techniques 431–2, 433
temporal lobe epilepsy 172
See also intraoperative
electrocoagulation; 
preoperative assessment
surround inhibition 20–1, 44–5
sylvian fissures 8
See also frontal lobe
epilepsy
symptomatic generalized epilepsy 116, 333–4
symptomatic (secondary) epilepsy
history 2
ILAE classification 131
myoclonus, epileptic 183
neuropathology 67–71
symptomatic seizures, acute 53, 189, 190, 299
synaptic anatomy/physiology, 18–19
synaptic function 62
synchronization, epileptogenesis in vitro 56
syncope
  cardiology assessment 299
  and cardiovascular syndromes 285–6
differential diagnosis 296–7
  EEG 214
  neurocardiogenic 286
treatment of 286
T calcium channels 28
T2000 398–9
talampanel 399
Task Force of the ILAE 118
teamwork. See joined-up primary–secondary care approach
telemetry 281, 284, 313–14, 315–16
temporal lobe epilepsy 168, 171, 173
  DTI 261–2
  memory impairment 262–3
temporal lobe seizures 110–11, 169
temporal lobe surgery 74, 449–50
tension, nervous 513
teratogenic effects, AEDs 539
ternal remission, definition 332
  toxin 49, 50
thalamic
clock theory 62
hypothesis 62
neurones 55
  relay neurones 54–5
stimulation 442, 443
therapeutic drug monitoring 359–62, 363, 366
  specific drugs 362–6
therapeutic ranges, AEDs 361–2, 366
theta brain waves 81
thresholds, seizure 533–5
  tiagabine 365, 383, 390, 404
tilt-table testing 286
time-limited psychotherapy 536–7
time trends, epidemiology of epilepsy 330
tiredness 513. See also behavioural treatment
tonabersat 399
tonic-clonic seizures 110–11
  tonic inhibition, GABA receptors 44
  seizures 111, 407
topiramate 365, 383, 390, 404
toxic, AEDs 300, 375–6, 392–3
tactography 260, 261. See also DTI
  trauma. See head injury
treatment. See management interventions
treatment gaps
developing world 555
  NHS 558
  triggers, epilepsy 284, 459–61
tuberculosis 67–8, 70, 181
  Tullio’s phenomenon 465
tumours 330–1, 500
  case scenarios, paediatric 308–9
  EEG 97
  and epilepsy. 497–9
  neuropathology 72–3
  PET 256
twilight states 522
2-deoxy-D-glucose 396–7
typical absence seizures 160, 164
UK
  disability legislation 570
  See also joined-up primary–secondary care approach
under-determined source localization 270–1
unilateral seizures, history 2
  unit costs 582–3
  unusual behaviours 534, 288–9
Unverricht-Lundborg disease 74, 185
urae mia 213–14
vagus nerve stimulation 436, 439, 441
  valproic acid 365, 388, 390, 487
valproemide 399–400
  variations, inter-individual 358
  vascular malformations 70–1
  vascular theories, history of epilepsy 2–3
  vasculo-degenerative dementia 213
vestibular stimuli, reflex epilepsy 459
video games, photosensitivity 462
video-EEG monitoring (video-telemetry) 281, 284, 313–14, 315–16
vigabatrin 135, 220–1, 365–6, 383, 390, 404
visual evoked cortical potentials 217–21
visual field defects 263–4
visual stimuli 459, 462–3.
  See also photosensitivity
visuospatial abilities, clinical neuropsychological evaluation 411
VMRI (volumetric MRI) 242
voltage clamp recordings 33
voltage-gated ion channels 22, 47–8, 353–7. See also calcium ion channels; potassium channels; sodium channels
voltage-gated K+ currents 47–8
voltage-sensitive sodium channels 347
volumetric acquisition 301
volumetric MRI 242
Wada test 61, 415–16, 423
  warning symptoms 110, 277, 515, 522
water safety 589
websites
  Epilepsy Action 564
  Epilepsy Bereaved 564
  Joint Epilepsy Council 564–5
  National Society for Epilepsy 564
  new AEDs 382
  pilots’ licences 554
  relevant organizations 552
Wernicke’s area 10
West syndrome 150–2, 200–3, 333–4
  white matter 8, 20, 259
  whole-cell patch clamps 32
  withdrawal, AED 401–2
  witnesses 276, 290, 291, 296–8
  women with epilepsy 474–7, 493.
  See also gender
  World Health Organization 3, 579–80
YKP3089 400
zonisamide 366, 383, 390, 404